However, in these trials, JAK2 burden was slightly reduced, indicating that JAK2 inhibitors are efficient to block the cytokine pathway responsible of the clinical symptoms in patients with MPN, but are not enough efficient to block the main molecular mechanism that originates the disease. This evidence concerns the gene JAK2 and myeloproliferative disorder.